Exhibit
10.2


 


STATEMENT
OF WORK #1


 


This
EAP STATEMENT OF WORK #1 (the “Statement of Work”) is effective this 30th day of May
2020 (“SOW Effective Date”) by and between Mateon Therapeutics INC., a Delaware corporation with
its principal office at 29397 Agoura Rd., Suite 107, Agoura Hills, CA 91301, USA (“Mateon”) and IMPATIENS
N.V. acting under the trade name myTomorrows, a company formed and registered under the laws of the Netherlands, and located
at Anthony Fokkerweg 61, 1059 CP, Amsterdam, The Netherlands (“Impatients”) will be incorporated into
the Expanded Access Program (EAP) Master Services Agreement between Mateon and Impatients dated 30h May 2020 (the “Agreement”).
Capitalized terms used in this Statement of Work will have the same meaning as set forth in the Agreement.


 


Mateon
hereby engages Impatients to provide Services, as follows:


 


		1.	Services.



 


Impatients
shall support Mateon with the setting up and executing of a Free of Charge Expanded Access Program in the Territory. The Services
shall include:


 


	 	●	Site
    management / physician engagement services 
	 	●	Patient
    qualification; eligibility check can be done by Mateon responsible medical person or myTomorrows 
	 	●	Guide
    and support physicians with per patient applications to regulatory authorities 
	 	●	Physician
    education, support, and training for approved EAP patient cases 
	 	●	Multi-lingual
    service provision 
	 	●	Forwarding
    of orders to Mateons’ supply chain department 
	 	●	Forwarding
    safety reports and product complaints sent to Impatients as required to Mateon applicable department 
	 	●	Project
    management & reporting


 


		2.	RWD
                                         Services.



 


	 	●	Database
    set-up
	 	●	Database
    programing 
	 	●	Protocol
    development
	 	●	Data
    monitoring


 


		3.	Fees



 


Set-up
Fee


 


Mateon
will pay to Impatients a set-up fee in the amount of USD 30,000 (thirty thousand US dollar), payable in two tranches: (i) first
tranche of USD 15,000 (fifteen thousand US dollar) payable upon signature of this Statement of Work; (ii) second tranche of USD
15,000 (fifteen thousand US dollar) payable upon treatment of the first patient.


 


Patient
Fee


 


At
the end of each month, Impatients will invoice Mateon a fee of USD 2,250 (two thousand two hundred and fifty US dollar) for each
patient treat with the Product under Expanded Access.


 


RWD
Service Fee


 


The
RWD collection shall be free of charge, provided that and for as long as Castor EDC provides the EDC to Impatients on a free of
charge basis for COVID-19 related research. Parties will mutually agree on a fee or discontinuation of the RWD services in case
Castor will charge Impatients for the use of the EDC.


 





 



SOW#1 Mateon & Impatients (MyTomorrows)


 



    	 	 	Page 1 | 2



     


    

 


	MATEON
    THERAPEUTICS, INC.	 	IMPATIENTS
    N.V. acting under the trade name myTomorrows
	 	 	 	 	 
	 	 	 	 	 
	By:
    	/s/
    Vuong Trieu	 	By:	/s/
    Pieter Erik de Ridders
	Print Name: 	Vuong
    Trieu	 	Print Name:	Pieter
    Erik de Ridders
	Title:
    	CEO	 	Title:	General
    Counsel
	Date:
    	24
    July 2020	 	Date:	23
    July 2020




 





 



SOW#1 Mateon & Impatients (MyTomorrows)


 




    	 	 	Page 2 | 2